secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001999371-26-010039
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix secures GPO coverage for TONMYA, expanding commercial access to ~35M patients
--------------------------------------------------------------------------------

- Agreement effective May 1, 2026 with leading GPO provides coverage for ~35M U.S. commercial lives (20% of ~177M total).
- TONMYA is the first new FDA-approved fibromyalgia treatment in over 15 years; commercially launched November 2025.
- TONMYA now covered under Medicaid in 38 states, representing ~55M beneficiaries (73% of ~75M Medicaid lives).
- Coverage includes standard utilization management criteria; patient savings program available for eligible commercially insured.
- CEO Seth Lederman emphasizes continued pursuit of additional commercial and government channel coverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126010039/0001999371-26-010039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126010039/tnxp_8k-050626.htm
  HTML page:      https://secwatch.observer/filing/0001999371-26-010039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer